https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e1191732
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-31 / Oncoimmunology 2016 Jul;5(7):e11917322016-05-31 00:00:002020-11-30 10:28:30Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-31 / J Gynecol Oncol 2016 Sep;27(5):e512016-05-31 00:00:002019-02-15 08:35:39Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-522016-05-24 00:00:002016-05-24 00:00:00Oncolytic virotherapy for urological cancers
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2016-05-15 13:50:092019-02-12 13:51:13Dr. Dirk Lorenzen stellt IOZK Immuntherapie in Shengzhou und Shanghai vor
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-14 / Cancers (Basel) 2016 May;8(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-14 / Cancers (Basel) 2016 May;8(5)2016-05-14 00:00:002019-02-15 08:39:28In Hyperthermia Increased ERK and WNT Signaling Suppress Colorectal Cancer Cell Growth
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-12 / J. Virol. 2016 06;90(11):5343-5352
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-12 / J. Virol. 2016 06;90(11):5343-53522016-05-12 00:00:002019-02-15 09:22:53Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-07 / Virus Res. 2016 08;221:23-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-07 / Virus Res. 2016 08;221:23-92016-05-07 00:00:002019-02-15 09:22:52Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-07 / World J. Gastroenterol. 2016 May;22(17):4275-862016-05-07 00:00:002019-02-15 08:39:08Dendritic cell-based cancer immunotherapy for colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2016-05-03 / Biomedicines 2016 May;4(2)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2016-05-03 / Biomedicines 2016 May;4(2)2016-05-03 00:00:002016-05-03 00:00:00Cancer Vaccines in Ovarian Cancer: How Can We Improve?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
IOZK
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
IOZK2016-05-01 13:48:072019-02-12 13:48:48Veröffentlichung von Stefaan Van Gool MD. PhD.: Electroporation of Dendritic Cells with WT1, Survivin, and TriMix
